97 related articles for article (PubMed ID: 21506705)
21. Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis.
Nosho K; Yamamoto H; Taniguchi H; Adachi Y; Yoshida Y; Arimura Y; Endo T; Hinoda Y; Imai K
Clin Cancer Res; 2004 Dec; 10(23):7950-7. PubMed ID: 15585629
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor.
Mroczko B; Lukaszewicz-Zajac M; Wereszczynska-Siemiatkowska U; Groblewska M; Gryko M; Kedra B; Jurkowska G; Szmitkowski M
Pancreas; 2009 Aug; 38(6):613-8. PubMed ID: 19629003
[TBL] [Abstract][Full Text] [Related]
23. Abnormal expression of insulin-like growth factor-II and its dynamic quantitative analysis at different stages of hepatocellular carcinoma development.
Qiu LW; Yao DF; Zong L; Lu YY; Huang H; Wu W; Wu XH
Hepatobiliary Pancreat Dis Int; 2008 Aug; 7(4):406-11. PubMed ID: 18693177
[TBL] [Abstract][Full Text] [Related]
24. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
Hoffmann U; Bertsch T; Dvortsak E; Liebetrau C; Lang S; Liebe V; Huhle G; Borggrefe M; Brueckmann M
Scand J Infect Dis; 2006; 38(10):867-72. PubMed ID: 17008230
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.
Määttä M; Soini Y; Liakka A; Autio-Harmainen H
Clin Cancer Res; 2000 Jul; 6(7):2726-34. PubMed ID: 10914717
[TBL] [Abstract][Full Text] [Related]
26. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer.
Kuropkat C; Plehn S; Herz U; Dünne AA; Renz H; Werner JA
Anticancer Res; 2002; 22(4):2221-7. PubMed ID: 12174907
[TBL] [Abstract][Full Text] [Related]
27. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
28. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
[TBL] [Abstract][Full Text] [Related]
29. Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization.
Daniele A; Divella R; Quaranta M; Mattioli V; Casamassima P; Paradiso A; Garrisi VM; Gadaleta CD; Gadaleta-Caldarola G; Savino E; Maci R; Bellizzi A; Fazio V
Clin Biochem; 2014 Feb; 47(3):184-90. PubMed ID: 24355694
[TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
31. Expression of matrix metalloproteinase-9 in predicting prognosis of hepatocellular carcinoma after liver transplantation.
Nart D; Yaman B; Yilmaz F; Zeytunlu M; Karasu Z; Kiliç M
Liver Transpl; 2010 May; 16(5):621-30. PubMed ID: 20440771
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of serum MMP-8, -9 and TIMP-1 in patients with hepatocellular carcinoma.
Lempinen M; Lyytinen I; Nordin A; Tervahartiala T; Mäkisalo H; Sorsa T; Isoniemi H
Ann Med; 2013 Nov; 45(7):482-7. PubMed ID: 23962148
[TBL] [Abstract][Full Text] [Related]
33. Increased levels of tissue inhibitor of metalloproteinase-1 in human hepatocellular carcinoma.
Matsumoto E; Nakatsukasa H; Nouso K; Kobayashi Y; Nakamura S; Suzuki M; Takuma Y; Tanaka H; Fujikawa T; Shiratori Y
Liver Int; 2004 Aug; 24(4):379-83. PubMed ID: 15287862
[TBL] [Abstract][Full Text] [Related]
34. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
[TBL] [Abstract][Full Text] [Related]
35. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival.
Miyata Y; Kanda S; Nomata K; Hayashida Y; Kanetake H
Urology; 2004 Mar; 63(3):602-8. PubMed ID: 15028476
[TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
[TBL] [Abstract][Full Text] [Related]
37. [Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats].
Chen RQ; Chen XM; Cui SW; Cai GY; Shi SZ; Xie YS; Lu Y; Peng LX
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):937-42. PubMed ID: 15329283
[TBL] [Abstract][Full Text] [Related]
38. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of PRL-3 expression, and its correlation with angiogenesis and invasion in hepatocellular carcinoma.
Zhao WB; Li Y; Liu X; Zhang LY; Wang X
Int J Mol Med; 2008 Aug; 22(2):187-92. PubMed ID: 18636172
[TBL] [Abstract][Full Text] [Related]
40. Basement membrane remodeling in skeletal muscles of patients with limb ischemia involves regulation of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases.
Baum O; Ganster M; Baumgartner I; Nieselt K; Djonov V
J Vasc Res; 2007; 44(3):202-13. PubMed ID: 17337906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
